Crism Therapeutics Corporation Response to Movement in Share Price
July 03 2024 - 11:18AM
RNS Regulatory News
RNS Number : 0420V
Crism Therapeutics Corporation
03 July 2024
The
information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014, as incorporated into UK law by
the European Union (Withdrawal) Act 2018. Upon the publication
of this announcement, this inside information is now considered to
be in the public domain.
03 July 2024
CRISM Therapeutics
Corporation
(AIM:CRTX)
Response to Movement in Share
Price
CRISM Therapeutics Corporation
("CRISM" or the "Company") notes the increase in the Company's
share price today and confirms that it is not aware of any specific
reason for the increase. The Company's share price has fallen since
admission to AIM (Admission) on 31 May 2024, and today's price
reversal reflects the Board's underlying view of the value of the
business. The Company continues to work on its stated strategy of
submitting a Clinical Trial Application in the second half of 2024
for its lead product, ChemoSeed. The Company is also at contract
stage to provide services with an early stage UK SME who are
seeking to utilise CRISM's drug formulation expertise. The value of
that contract would be approximately £230k + VAT. A further
announcement will be made in due course.
Enquiries:
|
Company
|
Nomad and
Broker
|
Financial
PR
|
|
CRISM Therapeutics
Corporation
|
S.P. Angel Corporate Finance
LLP
|
Buchanan
|
|
Andrew
Webb, CEO
Chris
McConville, CSO
|
Richard
Morrison
Adam
Cowl
|
Mark
Court mark.court@buchanancomms.co.uk
Jamie
Hooper jamie.hooper@buchanancomms.co.uk
|
|
via
Buchanan
|
+44 (0)
20 3470 0470
|
+44 (0)
20 7466 5000
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
SPMSSMFIDELSEFW
Crism Therapeutics (LSE:CRTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Crism Therapeutics (LSE:CRTX)
Historical Stock Chart
From Dec 2023 to Dec 2024
